[en] Dipeptidyl peptidase 4 (DPP-4) inhibitors (commonly referred to as gliptins) are a novel class of oral antihyperglycaemic agents with demonstrated efficacy in the treatment of type 2 diabetes mellitus (T2DM). Preclinical data and mechanistic studies have indicated a possible beneficial action on blood vessels and the heart, via both glucagon-like peptide 1 (GLP-1)-dependent and GLP-1-independent effects. DPP-4 inhibition increases the concentration of many peptides with potential vasoactive and cardioprotective effects. Clinically, DPP-4 inhibitors improve several risk factors in patients with T2DM. They improve blood glucose control (mainly by reducing postprandial glycaemia), are weight neutral (or even induce modest weight loss), lower blood pressure, improve postprandial lipaemia, reduce inflammatory markers, diminish oxidative stress, and improve endothelial function. Some positive effects on the heart have also been described in patients with ischaemic heart disease or congestive heart failure, although their clinical relevance requires further investigation. Post-hoc analyses of phase II-III, controlled trials suggest a possible cardioprotective effect with a trend for a lower incidence of major cardiovascular events with gliptins than with placebo or active agents. However, the actual relationship between DPP-4 inhibition and cardiovascular outcomes remains to be proven. Major prospective clinical trials with predefined cardiovascular outcomes and involving various DPP-4 inhibitors are now underway in patients with T2DM and a high-risk cardiovascular profile.
Seshasai, S. R. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829-841 (2011).
Hemmingsen, B. et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343, d6898 (2011).
Scheen, A. J. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63, 1165-1184 (2003).
Niswender, K. Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obes. Metab. 12, 267-287 (2010).
Ovalle, F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin. Ther. 33, 393-407 (2011).
Scheen, A. J. A review of gliptins in 2011. Expert Opin. Pharmacother. 13, 81-99 (2012).
Scott, L. J. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70, 2051-2072 (2010).
Scott, L. J. Linagliptin: in type 2 diabetes mellitus. Drugs 71, 611-624 (2011).
Yang, L. P. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs 72, 229-248 (2012).
Dhillon, S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70, 489-512 (2010).
Keating, G. M. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 70, 2089-2112 (2010).
Scheen, A. J. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 38, 89-101 (2012).
Phung, O. J., Scholle, J. M., Talwar, M. & Coleman, C. I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303, 1410-1418 (2010).
Gooßen, K. & Gräber, S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 14, 1061-1072 (2012).
Liu, S. C., Tu, Y. K., Chien, M. N. & Chien, K. L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes. Metab. 14, 810-820 (2012).
Amiel, S. A., Dixon, T., Mann, R. & Jameson, K. Hypoglycaemia in type 2 diabetes. Diabet. Med. 25, 245-254 (2008).
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R. & Tsapas, A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344, e1369 (2012).
Hermansen, K. & Mortensen, L. S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 30, 1127-1142 (2007).
Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577-1596 (2012).
Ussher, J. R. & Drucker, D. J. Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187-215 (2012).
Grieve, D. J., Cassidy, R. S. & Green, B. D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br. J. Pharmacol. 157, 1340-1351 (2009).
Ban, K., Hui, S., Drucker, D. J. & Husain, M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hypertens. 3, 245-259 (2009).
Chrysant, S. G. & Chrysant, G. S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 109, 1681-1685 (2012).
Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006).
Sivertsen, J., Rosenmeier, J., Holst, J. J. & Vilsbøll, T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209-222 (2012).
Monami, M. et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res. 2011, 215764 (2011).
Mundil, D., Cameron-Vendrig, A. & Husain, M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab. Vasc. Dis. Res. 9, 95-108 (2012).
Jose, T. & Inzucchi, S. E. Cardiovascular effects of the DPP-4 inhibitors. Diab. Vasc. Dis. Res. 9, 109-116 (2012).
Richter, B., Bandeira-Echtler, E., Bergerhoff, K. & Lerch, C. L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD006739 doi:10.1002/14651858.CD006739.pub2 (2008).
Murohara, T. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. J. Am. Coll. Cardiol. 59, 277-279 (2012).
Palmieri, F. E. & Ward, P. E. Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells. Adv. Exp. Med. Biol. 247A, 305-311 (1989).
Kirby, M., Yu, D. M., O'Connor, S. & Gorrell, M. D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. (Lond.) 118, 31-41 (2010).
Brandt, I. et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 52, 82-87 (2006).
Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835 (1993).
Mentlein, R., Dahms, P., Grandt, D. & Kruger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133-144 (1993).
Zaruba, M. M. et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4, 313-323 (2009).
Wang, L. H. et al. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides 12, 1357-1364 (1991).
Ban, K. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117, 2340-2350 (2008).
Fadini, G. P. et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1α. Diabetes Care 33, 1607-1609 (2010).
Huang, C. Y. et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br. J. Pharmacol. 167, 1506-1519 (2012).
Sauve, M. et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59, 1063-1073 (2010).
Glorie, L. L. et al. DPP4 inhibition improves functional outcome after renal ischemia reperfusion injury. Am. J. Physiol. Renal Physiol. 303, F681-F688 (2012).
Ye, Y. et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am. J. Physiol. Heart Circ. Physiol. 298, H1454-H1465 (2010).
Ye, Y., Perez-Polo, J. R., Aguilar, D. & Birnbaum, Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res. Cardiol. 106, 925-952 (2011).
Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B. & Berneis, K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin. Investig. Drugs 18, 1495-1503 (2009).
Monami, M., Iacomelli, I., Marchionni, N. & Mannucci, E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 20, 224-235 (2010).
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N. & Mannucci, E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab. Res. Rev. 27, 362-372 (2011).
Esposito, K. et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 13, 594-603 (2011
Fakhoury, W. K., Lereun, C. & Wright, D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86, 44-57 (2010).
Scheen, A. J., Charpentier, G., Ostgren, C. J., Hellqvist, A. & Gause-Nilsson, I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 26, 540-549 (2010).
Kim, W. & Egan, J. M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60, 470-512 (2008).
Pratley, R. E. et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes. Metab. 10, 931-938 (2008).
Baetta, R. & Corsini, A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 71, 1441-1467 (2011).
O'Keefe, J. H. & Bell, D. S. Postprandial hyperglycemia/ hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am. J. Cardiol. 100, 899-904 (2007).
Bonora, E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int. J. Clin. Pract. Suppl. 154, 19-28 (2007).
Mitri, J. & Hamdy, O. Diabetes medications and body weight. Expert Opin. Drug Saf. 8, 573-584 (2009).
Tahrani, A. A., Bailey, C. J., Del Prato, S. & Barnett, A. H. Management of type 2 diabetes: new and future developments in treatment. Lancet 378, 182-197 (2011).
Barnett, A., Allsworth, J., Jameson, K. & Mann, R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr. Med. Res. Opin. 23, 1493-1507 (2007).
Waters, S. B., Topp, B. G., Siler, S. Q. & Alexander, C. M. Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J. Diabetes Sci. Technol. 3, 68-82 (2009).
Foley, J. E. & Jordan, J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc. Health Risk Manag. 6, 541-548 (2010).
Russell-Jones, D. et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35, 252-258 (2012).
Bergenstal, R. M. et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376, 431-439 (2010).
Horton, E. S., Silberman, C., Davis, K. L. & Berria, R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33, 1759-1765 (2010).
Brown, N. J. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J. Am. Soc. Hypertens. 6, 163-168 (2012).
Marney, A., Kunchakarra, S., Byrne, L. & Brown, N. J. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56, 728-733 (2010).
Mistry, G. C. et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol. 48, 592-598 (2008).
Jackson, E. K. Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension 56, 581-583 (2010).
Ogawa, S. et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. J. Exp. Med. 223, 133-135 (2011).
Gutzwiller, J. P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055-3061 (2004).
Tanaka, T., Nangaku, M. & Nishiyama, A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr. Opin. Nephrol. Hypertens. 20, 476-481 (2011).
Rieg, T. et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Renal Physiol. 303, F963-F971 (2012).
Chaudhuri, A. & Dandona, P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes Obes. Metab. 13, 869-879 (2011).
Ansar, S., Koska, J. & Reaven, P. D. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc. Diabetol. 10, 61 (2011).
Farr, S. & Adeli, K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr. Opin. Lipidol. 23, 56-61 (2012).
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J. & Couture, P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes. Metab. 13, 366-373 (2011).
Matikainen, N. et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49, 2049-2057 (2006).
Boschmann, M. et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 94, 846-852 (2009).
Eliasson, B. et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 55, 915-925 (2012).
Hsieh, J. et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53, 552-561 (2010).
Monami, M., Lamanna, C., Desideri, C. M. & Mannucci, E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv. Ther. 29, 14-25 (2012).
Shah, Z. et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124, 2338-2349 (2011).
Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F. & Huang, Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 58, 157-166 (2011).
Derosa, G. et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59, 887-895 (2010).
Hattori, S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 58, 69-73 (2011).
Makdissi, A. et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97, 3333-3341 (2012).
Rizzo, M. R., Barbieri, M., Marfella, R. & Paolisso, G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35, 2076-2082 (2012).
Klempfner, R., Leor, J., Tenenbaum, A., Fisman, E. Z. & Goldenberg, I. Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. Cardiovasc. Diabetol. 11, 60 (2012).
Ceriello, A. et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697-702 (2011).
Koren, S. et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol. Ther. 14, 561-567 (2012).
Cersosimo, E. & DeFronzo, R. A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 22, 423-436 (2006).
Motta, A. J., Koska, J., Reaven, P. & Migrino, R. Q. Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat. Cardiovasc. Drug Discov. 7, 2-9 (2012).
Nystrom, T. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, E1209-E1215 (2004).
Mannucci, E. & Dicembrini, I. Incretin-based therapies and cardiovascular risk. Curr. Med. Res. Opin. 28, 715-721 (2012).
van Poppel, P. C., Netea, M. G., Smits, P. & Tack, C. J. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 34, 2072-2077 (2011).
Fadini, G. P. & Avogaro, A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul. Pharmacol. 55, 10-16 (2011).
Gupta, A. K., Verma, A. K., Kailashiya, J., Singh, S. K. & Kumar, N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 23, 565-570 (2012).
Sokos, G. G. et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100, 824-829 (2007).
Read, P. A., Khan, F. Z., Heck, P. M., Hoole, S. P. & Dutka, D. P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging 3, 195-201 (2010).
Ghadge, S. K., Muhlstedt, S., Ozcelik, C. & Bader, M. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther. 129, 97-108 (2011).
Post, S. et al. Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: Insights from the REPERATOR study. J. Mol. Cell. Cardiol. 53, 899-905 (2012).
Theiss, H. D. et al. Safety and efficacy of SITAgliptin plus Granulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int. J. Cardiol. 145, 282-284 (2010).
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D. & Shannon, R. P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12, 694-699 (2006).
Khan, M. A., Deaton, C., Rutter, M. K., Neyses, L. & Mamas, M. A. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail. Rev. http://dx.doi.org/10.1007/s10741-012-9318-y.
Vanderheyden, M. et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin. Chem. Lab. Med. 47, 248-252 (2009).
Goldfine, A. B. Assessing the cardiovascular safety of diabetes therapies. N. Engl. J. Med. 359, 1092-1095 (2008).
Anagnostis, P. et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes. Metab. 13, 302-312 (2011).
Monami, M., Dicembrini, I., Martelli, D. & Mannucci, E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr. Med. Res. Opin. 27 (Suppl. 3), 57-64 (2011).
Williams-Herman, D. et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr. Disord. 10, 7 (2010).
Schweizer, A. et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes. Metab. 12, 485-494 (2010).
Frederich, R. et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad. Med. 122, 16-27 (2010).
Cobble, M. E. & Frederich, R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc. Diabetol. 11, 6 (2012).
White, W. B. et al. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials [abstract]. Diabetes 59 (Suppl.), 391-PP (2010).
Johansen, O. E., Neubacher, D., von Eynatten, M., Patel, S. & Woerle, H. J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc. Diabetol. 11, 3 (2012).
Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475-483 (2012).
Fonseca, V. A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am. J. Cardiol. 108 (Suppl. 3), 52B-58B (2011).
Scirica, B. M. et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am. Heart J. 162, 818-825.e6 (2011).
White, W. B. et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am. Heart J. 162, 620-626.e1 (2011).
Rosenstock, J. et al. Rationale and design of the CAROLINA trial: An Active Comparator CARdiOvascular Outcome Study of the DPP-4 Inhibitor LINAgliptin in Patients With Type 2 Diabetes at High Cardiovascular Risk [abstract 1103-P]. Diabetes 60 (Suppl. 1), A303 (2011).
Bethel, M., Green, J., Califf, R. & Holman, R. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract]. Diabetes 58 (Suppl. 1), 2152 (2009).
van Genugten, R. E., van Raalte, D. H. & Diamant, M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes. Metab. 14, 101-111 (2012).
Drucker, D. J. Dipeptidyl peptidase 4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30, 1335-43 (2007).
Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007).
Shah, Z. et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul. Pharmacol. 55, 2-9 (2011).
Kröller-Schön, S. et al. Glucose Independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 96, 140-149 (2012).
Matsubara, J. et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 59, 265-276 (2012).
Shen, M. et al. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp. Diabetes Res. 2012, 146194 (2012).
Matsui, T., Nishino, Y., Takeuchi, M. & Yamagishi, S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol. Res. 63, 383-388 (2011).
Chaykovska, L. et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE 6, e27861 (2011).
Huisamen, B., Genis, A., Marais, E. & Lochner, A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc. Drugs Ther. 25, 13-20 (2011).
Lenski, M., Kazakov, A., Marx, N., Böhm, M. & Laufs, U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J. Mol. Cell. Cardiol. 51, 906-918 (2011).
Ferreira, L. et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010, 592760 (2010).
Gomez, N. et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 14, 14-21 (2012).
Chinda, K. et al. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int. J. Cardiol. 9, 256-269 (2012).
Apaijai, N., Pintana, H., Chattipakorn, S. C. & Chattipakorn, N. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology 153, 3878-3885 (2012).
Yin, M., Sillje, H. H., Meissner, M., van Gilst, W. H. & de Boer, R. A. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc. Diabetol. 10, 85 (2011).
Liu, L. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60, 833-841 (2012).
Pacheco, B. P. et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J. Hypertens. 29, 520-528 (2011).
Vaghasiya, J., Sheth, N., Bhalodia, Y. & Manek, R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul. Pept. 166, 48-54 (2011).
